Amivantamab

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Amivantamab is a drug catalogued in DrugCentral. It was first approved by the FDA in 2021. DrugCentral lists 2 molecular targets, including MET and EGFR. Recorded indications include Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.

• Molecular targets: MET and EGFR (2 listed in DrugCentral).
• Indications: Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.
• ATC code: L01FX18 (Other monoclonal antibodies and antibody drug conjugates).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations

Mechanism & targets

Molecular targets (2)

Target	Gene	Action	Activity
Hepatocyte growth factor receptor	MET	other	Kd 10.40
Epidermal growth factor receptor	EGFR	other	Kd 8.84

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2021-09-12	EMA	—	Janssen-Cilag International N.V.
2021-05-21	FDA	—	JANSSEN BIOTECH

ATC classification

ATC code	Therapeutic hierarchy
L01FX18	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• EMA label: EGFR · Testing Required
• FDA label: EGFR · Testing Required
• HCSC label: EGFR · Testing Required

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Infusion related reaction	1622.3
Paronychia	665.0
Rash	510.1
Dermatitis acneiform	379.3
Skin toxicity	332.9
Non-small cell lung cancer	220.7
Hypoalbuminaemia	163.6
Mucosal inflammation	128.4
Pulmonary embolism	120.9
Pneumonitis	114.4
Flushing	99.4
Embolism venous	94.9

Chemical structure

• Molecular formula: —
• Molecular weight: —
• CAS number: —
• InChIKey: —
• PubChem CID: —

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Amivantamab used for?

DrugCentral lists the following indications for Amivantamab: Advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.

How does Amivantamab work?

Its molecular targets in DrugCentral include MET and EGFR.

When was Amivantamab first approved?

Amivantamab was first approved by the FDA in 2021.

Sources

• DrugCentral drug card 5463 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL4297774 — compound record and bioactivity
• DrugBank DB16695 — drug record
• FDA UNII 0JSR7Z0NB6 — substance identity
• DailyMed: FDA labels for Amivantamab — current prescribing information (label search)
• UniProt P08581 (MET) — target protein
• UniProt P00533 (EGFR) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.